spironolactone has been researched along with Cruveilhier-Baumgarten Syndrome in 32 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 9.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| "Five patients with liver cirrhosis, portal hypertension and oesophageal varices received spironolactone in daily doses of 50-200 mg." | 7.67 | [Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?]. ( Klein, CP, 1985) |
| "The effect of spironolactone on esophageal variceal pressure (VP) in patients without ascites was investigated." | 5.08 | The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. ( Fevery, J; Lijnen, P; Nevens, F; VanBilloen, H, 1996) |
| "Five patients with liver cirrhosis, portal hypertension and oesophageal varices received spironolactone in daily doses of 50-200 mg." | 3.67 | [Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?]. ( Klein, CP, 1985) |
| "Portal hypertension is one of the main consequences of cirrhosis." | 2.43 | Current management of the complications of portal hypertension: variceal bleeding and ascites. ( Calès, P; Dib, N; Oberti, F, 2006) |
| "Terlipressin has longer effects and is more effective and safer than vasopressin alone or in combination with nitroglycerin." | 2.41 | The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. ( Bosch, J, 2000) |
| "Spironolactone, which has been shown to lower HVPG in patients with cirrhosis, produces a reduction in plasma volume that attenuates the increased cardiac output associated with cirrhosis and triggers vasoactive mechanisms that decrease splanchnic blood flow." | 2.38 | New approaches in the pharmacologic treatment of portal hypertension. ( Bosch, J; Fernández, M; Feu, F; García-Pagán, JC; Luca, A; Pizcueta, P; Rodés, J, 1993) |
| "Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension." | 1.34 | [Portopulmonary hypertension due to schistosomiasis in two Malagasy patients]. ( Rajaona, HR; Rajaonarivelo, P; Ramanampamonjy, RM; Razafimahefa, SH, 2007) |
| " Our aim was to study the hemodynamic effects of the early and chronic administration of PR and spironolactone (SPN), alone or in combination, in a model of hepatic fibrosis and sinusoidal portal hypertension induced in rats by bile duct ligation." | 1.30 | Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. ( Calès, P; Douay, O; Gallois, Y; Le Jeune, JJ; Maïga, MY; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL, 1997) |
| " These results show that long-term administration of spironolactone to patients with cirrhosis and no ascites produced a significant reduction in HVPG that may have been due to gradual, sustained volume contraction." | 1.29 | Plasma volume contraction in portal hypertension. ( Aramaki, T; Katsuta, Y; Okumura K [corrected to Okumura, H]; Okumura, H; Satomura, K; Sekiyama, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (40.63) | 18.7374 |
| 1990's | 13 (40.63) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celtik, C | 1 |
| Durmaz, O | 1 |
| Oner, N | 1 |
| Yavuz, T | 1 |
| Gökce, S | 1 |
| Aydogan, A | 1 |
| Nisli, K | 1 |
| Emiroglu, HH | 1 |
| Ömeroglu, RE | 1 |
| Sökücü, S | 1 |
| Hou, W | 1 |
| Sanyal, AJ | 1 |
| VOLWILER, W | 1 |
| CHAPIS, NJ | 1 |
| Dib, N | 1 |
| Oberti, F | 3 |
| Calès, P | 3 |
| Ramanampamonjy, RM | 1 |
| Razafimahefa, SH | 1 |
| Rajaonarivelo, P | 1 |
| Rajaona, HR | 1 |
| Giannarelli, C | 1 |
| De Giorgi, A | 1 |
| De Negri, F | 1 |
| Carmassi, F | 1 |
| Dorner, M | 1 |
| Frey, G | 1 |
| Zapater, P | 1 |
| Alba, D | 1 |
| Bosch, J | 3 |
| García-Pagán, JC | 2 |
| Feu, F | 2 |
| Luca, A | 2 |
| Fernández, M | 1 |
| Pizcueta, P | 2 |
| Rodés, J | 1 |
| Salmerón, JM | 1 |
| Ginés, P | 1 |
| Claria, J | 1 |
| Piera, C | 1 |
| Arroyo, V | 1 |
| Katsuta, Y | 1 |
| Aramaki, T | 1 |
| Sekiyama, T | 1 |
| Satomura, K | 1 |
| Okumura, H | 1 |
| Okumura K [corrected to Okumura, H] | 1 |
| Nevens, F | 2 |
| Lijnen, P | 1 |
| VanBilloen, H | 1 |
| Fevery, J | 1 |
| Imai, F | 1 |
| Sugano, S | 2 |
| Suzuki, T | 1 |
| Nishio, M | 1 |
| Makino, H | 1 |
| Okajima, T | 2 |
| Rifflet, H | 2 |
| Maïga, MY | 2 |
| Pilette, C | 2 |
| Gallois, Y | 2 |
| Douay, O | 1 |
| Le Jeune, JJ | 2 |
| Saumet, JL | 2 |
| Moreau, A | 1 |
| Girault, A | 1 |
| le Bouil, A | 1 |
| Feldmann, G | 1 |
| Kawafune, T | 1 |
| Ishii, K | 1 |
| Watanabe, M | 1 |
| Takamura, N | 1 |
| Müting, D | 1 |
| Fischer, R | 1 |
| Ordnung, W | 1 |
| Potter, C | 1 |
| Willis, D | 1 |
| Sharp, HL | 1 |
| Scharzenberg, SJ | 1 |
| Duclos, B | 1 |
| Bories, P | 1 |
| Mathieu-Daude, JC | 1 |
| Michel, H | 1 |
| Klein, CP | 1 |
| Inberg, MV | 1 |
| Harjola, PT | 1 |
| Scheinin, TM | 1 |
| Conn, HO | 1 |
| Felder, KD | 1 |
| Wernze, H | 1 |
| Brunswig, D | 1 |
| Wohlenberg, H | 1 |
| Huchzermeyer, H | 1 |
| Kommerell, B | 1 |
| Weinreich, J | 1 |
6 reviews available for spironolactone and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Ascites: diagnosis and management.
Topics: Ascites; Ascitic Fluid; Cardiac Output; Diet, Sodium-Restricted; Disease Progression; Diuretics; Dru | 2009 |
Current management of the complications of portal hypertension: variceal bleeding and ascites.
Topics: Algorithms; Anti-Bacterial Agents; Ascites; Collateral Circulation; Diuretics; Endoscopy, Gastrointe | 2006 |
New approaches in the pharmacologic treatment of portal hypertension.
Topics: Adrenergic beta-Antagonists; Humans; Hypertension, Portal; Propranolol; Serotonin Antagonists; Spiro | 1993 |
[Drug therapy for the treatment of portal hypertension].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Combined Modality Therapy; Diuretics; Female; Humans; Hype | 1996 |
The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination | 2000 |
The rational management of ascites.
Topics: Albumins; Aldosterone; Animals; Ascites; Ascitic Fluid; Diet, Sodium-Restricted; Diuretics; Dogs; Dr | 1972 |
4 trials available for spironolactone and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Ascites; Atrial Natriuretic Factor; | 1996 |
Non-invasive variceal pressure measurements: validation and clinical implications.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Determination; Double-Blind Method; Esophageal | 1996 |
Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis.
Topics: Administration, Cutaneous; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esopha | 1997 |
Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.
Topics: Diuretics; Female; Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; P | 1998 |
22 other studies available for spironolactone and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension.
Topics: Adolescent; Antihypertensive Agents; Ascites; Blood Pressure; Cardiomyopathies; Case-Control Studies | 2015 |
CIRRHOSIS--FLUID RETENTION AND ASCITES.
Topics: Ascites; Chlorothiazide; Diet; Diet Therapy; Diuretics; Edema; Humans; Hypertension; Hypertension, P | 1964 |
PORTACAVAL SHUNT PERFORMED DURING PREGNANCY.
Topics: Chlorothiazide; Diet, Sodium-Restricted; Esophageal and Gastric Varices; Female; Gastrointestinal He | 1964 |
[Portopulmonary hypertension due to schistosomiasis in two Malagasy patients].
Topics: Adolescent; Adult; Anthelmintics; Ascites; Combined Modality Therapy; Diet, Sodium-Restricted; Dyspn | 2007 |
Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diet, Sodium-Restricted; Di | 2007 |
[Saluretics in liver diseases].
Topics: Ammonium Chloride; Ascites; Capillary Permeability; Diuretics; Humans; Hypertension, Portal; Hypopro | 1966 |
Acidosis and extreme hyperkalemia associated with cholestyramine and spironolactone.
Topics: Acidosis; Cholestyramine Resin; Humans; Hyperkalemia; Hypertension, Portal; Liver Cirrhosis, Alcohol | 1995 |
Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis.
Topics: Aged; Azygos Vein; Combined Modality Therapy; Diet, Sodium-Restricted; Female; Hemodynamics; Hepatic | 1994 |
Plasma volume contraction in portal hypertension.
Topics: Aged; Aldosterone; Blood Pressure; Dose-Response Relationship, Drug; Female; Furosemide; Hemodynamic | 1993 |
Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.
Topics: Animals; Antihypertensive Agents; Cholestasis; Drug Evaluation, Preclinical; Drug Therapy, Combinati | 1997 |
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Topics: Animals; Bile Ducts; Blood Pressure; Double-Blind Method; Hemodynamics; Hypertension, Portal; Hypoli | 1997 |
[Portal hypertension from the internal medicine viewpoint].
Topics: Furosemide; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Spironolactone; Vasopressins | 1976 |
Primary and secondary amenorrhea associated with spironolactone therapy in chronic liver disease.
Topics: Adolescent; Adult; Amenorrhea; Cholestasis; Chronic Disease; Female; Humans; Hypertension, Portal; H | 1992 |
Jejunal permeability to water and electrolytes in patients with chronic intrahepatic hypertension: evidence for a role of aldosterone.
Topics: Adult; Aged; Aldosterone; Chlorides; Electrolytes; Female; Humans; Hypertension, Portal; Intestinal | 1991 |
[Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?].
Topics: Blood Pressure Determination; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Spironola | 1985 |
Role of the mesentericocaval shunt in the management of portal hypertension.
Topics: Adolescent; Adult; Diuretics; Duodenal Ulcer; Edema; Female; Follow-Up Studies; Gastrointestinal Hem | 1974 |
[Pregnancy in liver cirrhosis. Internal medicine and gynecological aspects].
Topics: Adult; Ascites; Colon; Diet, Sodium-Restricted; Diuretics; Esophageal and Gastric Varices; Esophagea | 1973 |
Medical grand rounds from the University of Alabama Medical Center.
Topics: Alcoholism; Antacids; Ascites; Biopsy; Blood Transfusion; Collateral Circulation; Esophageal and Gas | 1969 |
[Myelofibrosis and esophageal varices].
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Por | 1969 |
[Ascites in pregnancy in liver cirrhosis].
Topics: Ascites; Diet, Sodium-Restricted; Female; Fetal Death; Humans; Hypertension, Portal; Infant, Newborn | 1970 |
[Therapy of liver cirrhosis].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Diet Therapy; Hepatic Encephalopathy; Humans; Hypertension | 1971 |
[Portal hypertension in chronic liver diseases and its therapy].
Topics: Ascites; Chronic Disease; Esophageal and Gastric Varices; Humans; Hypertension, Portal; Liver Cirrho | 1969 |